Jonathan Siegal Sells 545 Shares of Vericel Co. (NASDAQ:VCEL) Stock

Vericel Co. (NASDAQ:VCEL) insider Jonathan Siegal sold 545 shares of the firm’s stock in a transaction on Friday, July 5th. The shares were sold at an average price of $45.00, for a total transaction of $24,525.00. Following the sale, the insider now owns 1,033 shares in the company, valued at $46,485. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.

Vericel Stock Down 1.3 %

Shares of VCEL stock opened at $45.45 on Thursday. The stock has a market cap of $2.21 billion, a P/E ratio of -4,540.46 and a beta of 1.70. Vericel Co. has a 52 week low of $30.18 and a 52 week high of $53.05. The company’s fifty day simple moving average is $46.50 and its two-hundred day simple moving average is $45.14.

Vericel (NASDAQ:VCEL) last announced its quarterly earnings results on Wednesday, May 8th. The biotechnology company reported ($0.08) EPS for the quarter, topping the consensus estimate of ($0.11) by $0.03. The business had revenue of $51.28 million for the quarter, compared to analysts’ expectations of $49.07 million. Vericel had a net margin of 0.22% and a return on equity of 0.21%. The business’s quarterly revenue was up 25.0% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.16) EPS. On average, analysts anticipate that Vericel Co. will post 0.11 EPS for the current fiscal year.

Institutional Trading of Vericel

A number of large investors have recently made changes to their positions in the business. Vanguard Group Inc. increased its holdings in shares of Vericel by 1.2% in the 1st quarter. Vanguard Group Inc. now owns 3,413,442 shares of the biotechnology company’s stock worth $177,567,000 after buying an additional 39,349 shares during the last quarter. Conestoga Capital Advisors LLC increased its holdings in shares of Vericel by 4.9% in the 4th quarter. Conestoga Capital Advisors LLC now owns 2,339,960 shares of the biotechnology company’s stock worth $83,326,000 after buying an additional 109,215 shares during the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. increased its holdings in shares of Vericel by 10.9% in the 1st quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 1,021,695 shares of the biotechnology company’s stock worth $53,149,000 after buying an additional 100,797 shares during the last quarter. William Blair Investment Management LLC increased its holdings in shares of Vericel by 0.8% in the 1st quarter. William Blair Investment Management LLC now owns 841,677 shares of the biotechnology company’s stock worth $43,784,000 after buying an additional 6,792 shares during the last quarter. Finally, Congress Asset Management Co. MA increased its holdings in shares of Vericel by 509.1% in the 1st quarter. Congress Asset Management Co. MA now owns 836,481 shares of the biotechnology company’s stock worth $43,514,000 after buying an additional 699,147 shares during the last quarter.

Analyst Ratings Changes

Several analysts have recently commented on the stock. StockNews.com upgraded shares of Vericel from a “sell” rating to a “hold” rating in a research report on Friday, June 21st. HC Wainwright raised their price objective on shares of Vericel from $53.00 to $55.00 and gave the company a “buy” rating in a research report on Thursday, May 9th. TD Cowen initiated coverage on shares of Vericel in a research report on Thursday, June 20th. They set a “buy” rating and a $55.00 price objective on the stock. Finally, Truist Financial reiterated a “buy” rating and issued a $54.00 price target on shares of Vericel in a report on Tuesday, March 26th. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $48.17.

About Vericel

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.